Publications
It Takes Two to Tango: When do Conditional Reimbursement Risk-Sharing Schemes Work for Both Parties?
1 December 2021
Faster regulatory approval has not necessarily achieved faster patient access. A new OHE paper sets out how risk-sharing can tackle this, enabling resolution of differences of…
2020 OHE Annual Report to the Charity Commission
1 December 2021
We are pleased to submit the third report to the Charity Commission for England and Wales, OHE’s second since becoming a registered charity in December 2016.…
After the Transplant: Potential Benefits for the NHS and UK Kidney Transplant Patients
1 November 2021
Around 10% of people in the United Kingdom (UK) have chronic kidney disease (CKD) according to Kidney Care UK. While CKD can be managed through diet and…
Payment Models for Multi-Indication Therapies
1 November 2021
For the growing number of multi-indication medicines, access may be delayed or even denied due to challenges in linking payment with a medicine’s value across those…
The Value of Vaccines in Maintaining Health System Capacity in England
1 October 2021
This report has now been published as an article in Value in Health available here. The NHS is facing unprecedented health system pressure, with a record number…
Working Towards a Sustainable, Healthy Market for Vaccines: a Comprehensive Framework to Support Policy Dialogue and Decision-Making
1 September 2021
By placing a strain on health care systems and the global economy, the COVID-19 pandemic clearly shows the need to more comprehensively understand both supply- and…
The Lower Drug Costs Now Act and Pharmaceutical Innovation
1 September 2021
The US spends significantly more on healthcare per person than other wealthy countries. H.R. 3 is a recent policy proposal aimed at reducing national spending on…
A Case Study Analysis: Challenges in the NICE Evaluation of Multi-Indication Medicines for Rare and Ultra-Rare Diseases
1 September 2021
Medicines for rare and ultra-rare conditions face distinct economic and ethical challenges compared to medicines for more common conditions. These challenges are implicitly acknowledged by the…
How is Quality of Life Measured for Health Technology Assessments?
1 July 2021
Cost-effectiveness analysis (CEA) is the economic evaluation method that is typically preferred by health technology assessment agencies. Quality-adjusted life years (QALYs) – a composite measure of quality and…